An empathetic and non-judgmental approach facilitates discussions sensitive to gender, culture, ethnicity, and other differences. The focus is using an individual s risk factors and event history to guide the various treatment and management strategies among patients at risk for CVD morbidity and mortality. F. Highlighted Features of this Clinical Practice Guideline The 2020 edition of the VA/DoD Dyslipidemia CPG is the fourth update to the original CPG. It provides practice recommendations for the management of dyslipidemia. a. Methodology Particular strengths of this CPG include adherence to the National Academy of Medicine s (NAM) eight principles of trustworthy guidelines, including the management of COI, interdisciplinary stakeholder involvement, and representation from the broad spectrum of providers engaged in the treatment and management of dyslipidemia.[17] This CPG also uses GRADE methodology, which allows the systematic consideration of factors beyond the strength of the evidence, including balancing desired outcomes with potential harms of the intervention, equity of resource availability, the potential for variation in patient values and preferences, and other considerations (e.g., resource use, subgroup considerations) as appropriate. Applicability of the evidence to VA/DoD populations was also considered. The GRADE methodology allows for explicit recommendations on how primary care providers may improve efficiency in clinic and incorporate patient-centered clinical outcomes. A simple one page algorithm accompanies the guideline and provides an overview of the recommendations in the context of the flow of patient care and to assist with training providers (see the Algorithm section). The algorithm may be used to help facilitate the translation of guideline recommendations into effective practice. Finally, this CPG includes the newest U.S. Food and Drug Administration (FDA) approved dyslipidemia treatments (e.g.